The NeoRHEA trial showed that treatment with palbociclib and endocrine therapy decreases T cell proliferation and the presence of tissue-resident memory T cells. These results are important for the development of CDK4 selective inhibitors.
- Andreas Papagiannis
- Samira Majjaj
- Michail Ignatiadis
